BCL2 and B-cell chronic lymphocytic leukemia: In CLL, EZH2 inhibition has an anti-tumor effect, which suggests that miR-138 is a potential therapeutic target [94]. Besides that, miR-138 influences CD-95-mediated apoptosis and stimulates this process by increasing BAX and decreasing BCL-2, which will activate caspase-3 and lead to cell death [92].